Article

Biologic Therapies Benefit Psoriasis Patients with Depression

Author(s):

Biologic therapies, such as tumor necrosis factor (TNF) inhibitors, can potentially mitigate symptoms of depression and insomnia in patients with psoriasis and psoriatic arthritis.

Biologic therapies, such as tumor necrosis factor (TNF) inhibitors, can potentially mitigate symptoms of depression and insomnia in patients with psoriasis and psoriatic arthritis.

The study, published in Medicine, investigated the effects of biologics on psoriasis patients’ psychological symptoms and wellbeing.

According to the National Psoriasis Foundation and prior studies, psychological symptoms in psoriasis patients are more common than in patients with other skin-disfiguring diseases, and may be as prevalent as in other major clinical diseases like cancer and diabetes.

As such, researchers from Chinese medical and research institutions identified 980 patients with psoriasis or psoriatic arthritis who had received treatment with biologics like TNF inhibitors from 2009 to 2012.

The team wanted to assess and compare the rates of such patients undergoing treatment for depression and insomnia before and after biologic therapy.

The study results indicated that before beginning biologic therapy, nearly 20% of patients were regularly taking antidepressants. However, two years of treatment with biologics showed an approximately 40% decrease in the prevalence of antidepressant use.

Additionally, patients younger than 45 on biologic therapy who were not diagnosed with psoriatic arthritis exhibited a significant reduction in depression and insomnia compared to other patients.

The authors concluded, “The results suggest that biologic therapy may be associated with reduced rates of depression and insomnia, and a reduced rate of regular antidepressant use in psoriasis patients.”

Related Videos
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Implications of Findings on Patient-Reported Outcomes for Roflumilast Foam, with Melinda Gooderham, MD
New Findings on Psoriasis Outcomes for Roflumilast Foam 0.3%, with Melinda Gooderham, MD
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
2 Additional Clinical Pearls for Dermatologists, with Eingun James Song, MD
© 2024 MJH Life Sciences

All rights reserved.